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Dementia prevalence continues to increase, and effective interventions are needed to prevent, 
delay, or slow its progression. Higher adherence to the Mediterranean diet (MedDiet) and 
increased physical activity (PA) have been proposed as strategies to facilitate healthy brain 
ageing and reduce dementia risk. However, to date, there have been no dementia prevention 
trials in the UK focused on combined dietary and PA interventions. This study aims to: 1) 
assess the feasibility and acceptability of a multi-domain intervention for dementia risk 
reduction in an ‘at risk’ UK cohort; 2) evaluate behaviour change responses to the intervention; 
and, 3) provide information on cognitive, neurological, vascular and physiological outcomes 
to inform the design of a follow-on, full-scale efficacy trial.  
 
Methods 
One hundred and eight participants aged 55-74 years with a QRISK2 score of ≥10% will be 
recruited to take part in this 24-week multi-site study. Participants will be randomised into 
three parallel arms: 1) Control; 2) MedDiet; 3) MedDiet+PA. The study will apply a 
personalised, multi-domain intervention to increase MedDiet adherence and/or PA levels in 
older adults at risk of dementia. Diet and PA will be monitored prior to, during, and following 
the intervention. Feasibility and acceptability of our multi-domain intervention will be assessed 
in addition to measures of cognitive function (extended Neuropsychological Test Battery), 
brain structure/perfusion (MRI), vascular function (blood pressure and endothelial function) 





This trial will provide insights into the feasibility and acceptability of a multi-domain 
intervention for dementia risk reduction in an ‘at risk’ UK cohort.   
 
Ethics and dissemination 
The study has received NHS REC and HRA approval (18/NI/0191). Findings will be 
disseminated via conference presentations and peer-reviewed publications.    
 







STRENGTHS AND LIMITATIONS OF THIS STUDY 
• MedEx-UK is the first feasibility and acceptability study of a Mediterranean diet 
(MedDiet) alone or in combination with physical activity (PA) intervention for 
dementia risk reduction in an ‘at-risk’ UK cohort.  
• This study will provide detailed information on behavioural (dietary and objective 
measures of PA), cognitive, neurological, vascular and physiological outcomes to 
inform the design of a follow-on, full-scale efficacy trial. 
• The study intervention is informed by evidence synthesis and was designed with input 
from patients and members of the public. 
• It is not possible to blind participants to their experimental condition, and results may 
be influenced by expectation bias.  
• It is beyond the scope of this trial to include a PA only arm so that the effects of PA 





The worldwide prevalence of dementia continues to increase – an effect driven by expanding 
and ageing populations. Current estimates suggest that around 50 million individuals 
worldwide have dementia, with this figure forecast to increase to around 82 million by 2030 
and 152 million by 2050 [1]. In England and Wales, dementia is the first and second leading 
cause of death in women and men, respectively, responsible for 16.7 % and 8.9 % of total 
mortality in 2018 [2]. Considering the health and social care burden and financial cost of 
dementia, estimated to be £26.3 billion (£32,250 per affected person) in the UK in 2014 [3], 
identifying ways to prevent, delay, or slow the progression of dementia is a major public health 
and research priority [4]. There is no cure for dementia, and there are few pharmacological 
options to improve symptoms [5]. However, an increasingly large body of evidence indicates 
that modifiable behaviours such as diet and physical activity (PA) could play an important role 
in preventing or delaying dementia onset [4,6]. Delaying the onset by 2 or 5 years is estimated 
to reduce the number of dementia cases by 19% and 33%, respectively, by 2050, with a lower 
prevalence of severe dementia [7]. 
 
The Mediterranean dietary pattern (MedDiet) is one of the healthiest dietary patterns and is 
characterised by high intakes of vegetables, fruits, nuts, seeds, and whole grains. Fish and other 
seafood are consumed at least twice per week, whilst red meat and confectionery are consumed 
infrequently. Olive oil is the principal cooking fat, whilst red wine is consumed in moderation 
with meals [8,9]. Several prospective cohort studies have reported reduced brain atrophy, better 
cognitive function and reduced risk of dementia, including Alzheimer’s disease, with higher 
MedDiet adherence [10,11]. Adherence to a Mediterranean diet was identified to play a key 
role in dementia prevention, intervention and care by the Lancet commission [11].  Moreover, 
evidence from the Prevención con Dieta Mediterránea (PREDIMED) randomised controlled 
trial (RCT) in Spain demonstrated beneficial effects on cognitive function of a MedDiet 
intervention supplemented with additional nuts or extra virgin olive oil [12–14].  Fewer studies 
have been conducted outside the Mediterranean basin. However, in a recent analysis of over 
8000 participants from the EPIC-Norfolk cohort (UK), we demonstrated that a 3 point increase 
in MedDiet score on a 14- or 15-point scale was equivalent to between 1.5 and 5 fewer years 
of ageing on global cognition, with effects particularly evident in individuals at higher 
cardiovascular disease (CVD) risk [15].  Potential mechanisms of action for the MedDiet 
include improved cardiovascular health [16,17] and modulation of the gut microbiota [18] 
along with direct effects on brain glucose utilisation and β-amyloid load [19,20].  
 
Increased PA has also been shown to reduce age-related cognitive decline and dementia risk 
[21,22]. In a recent dose-response meta-analysis, the risk of all-cause dementia and 
Alzheimer’s disease was found to be 10% and 13% lower, respectively, for every 500 kcal or 
10 metabolic equivalent (MET)-hours per week increase in leisure-time PA [21]. While there 
is strong evidence of a protective effect of PA in numerous observational studies, the limited 
number of RCTs and the heterogeneity of the exercises prescribed in these studies, limit our 
understanding of the effects [23–25]. Potential mechanisms for the effects of PA on cognitive 
health include induction of antioxidant pathways, reduced neuro-inflammation, neurogenesis, 
enhanced synaptic plasticity, decreased amyloid burden, improved vessel health and 
augmented cerebrovascular blood flow [26–30].  
 
The effects of increased PA and improved diet on cognitive health are likely to be additive. To 
date, three large-scale multi-domain interventions have been completed which incorporated 
diet and increased PA [31–33]. The Finnish Geriatric Intervention Study to Prevent Cognitive 
Impairment and Disability (FINGER) trial – which included dietary advice, PA, cognitive 
training, social activity, and management of metabolic and vascular risk factors - observed 25-
150 % improvement in cognitive outcomes [31]. In addition, the Prevention of Dementia by 
Intensive Vascular Care (preDIVA, The Netherlands), which included lifestyle (diet, PA, 
smoking cessation) and medical interventions (e.g. statins, anti-hypertensive medication), and 
the Multidomain Alzheimer Preventive Trial (MAPT, France) trial, which included dietary and 
PA changes alongside cognitive stimulation, observed protective effects in specific sub-groups 
including individuals with elevated vascular or dementia risk, brain amyloid positivity, or 
APOE4 carriers [32,33]. Two ongoing studies – the Lifestyle Intervention in Independent 
Living Aged Care (LIILAC) [34] and Maintain Your Brain (MYB) [35] trials – are 
investigating the combined impact of a MedDiet and PA intervention on cognition in Australian 
populations.  
 
To date, there have been no dementia prevention trials in the UK focused on MedDiet only or 
in combination with PA. Given a) the lack of success of pharmacological trials, b) the 
widespread calls for dementia risk reduction strategies in the UK, and c) the effectiveness of 
multi-domain interventions such as FINGER, preDIVA and MAPT in improving cognitive 
function, this research is strongly justified. The aims of the MedEx-UK are: 
 
1) To assess the feasibility and acceptability of a multi-domain intervention by evaluating 
participant recruitment, engagement and retention on the trial. 
2) To assess behavioural change in response to the intervention through changes in 
MedDiet scores and PA levels. 
3) To assess various cognitive, neurological, vascular and biological outcomes to inform 
the design of a later full-scale efficacy trial.   
 
 METHODS AND ANALYSIS 
This protocol has been written in accordance with the Standard Protocol Items for Randomised 
Trials (SPIRIT) guidelines  [36] 
 
Design 
MedEx-UK is a 24-week multi-site (Norwich, Newcastle and Birmingham) RCT in older UK 
adults at risk of dementia. The study is a personalised, multi-domain intervention, with three 
parallel arms: 1) Control; 2) MedDiet; 3) MedDiet+PA.    
 
Participants 
We are recruiting 108 participants (36 per site) through Primary Care and direct-to-public 
advertisements such as via posters, leaflet distribution, social media and local media. 
Recruitment through Primary Care is in collaboration with local Clinical Research Networks 
(CRNs) at each study site.  
 
Inclusion and exclusion criteria 
Participants are aged 55 to 74 years. Cardiovascular health is highly prognostic of future 
dementia [37–40]. The QRISK2 score is routinely in UK primary care, to identify 
cardiovascular risk and is applied in MedEx to identify those ‘at risk’ for dementia. We 
included those with a QRISK2 score of ≥10%, which indicates a ≥10% risk of having a 
cardiovascular event in the next 10y. Participants will i) possess normal cognition (Montreal 
Cognitive Assessment (MoCA) score ≥23 [35]), ii) not diagnosed with mild cognitive 
impairment, dementia or any other severe neuropsychological complaints, iii) have a baseline 
MedDiet (Mediterranean Diet Adherence Screener (MEDAS)) score ≤9 [41]; and iv) undertake 
<90 minutes moderate-intensity PA per week. We estimate that our recruitment strategy will 
identify 10-15% of the 55-74 year old UK population who are at risk of dementia and are likely 
to benefit from behavioural change. A full list of criteria is provided in Table 1.   
 
Recruitment 
Prior to enrolment, participants undergo several stages of screening to ensure they meet the 
study inclusion/ exclusion criteria (Figure 1).  
 
Online screening 
Participants provide online consent prior to completing an online screening questionnaire (~30 
minutes duration). This questionnaire evaluates a MedDiet adherence score via an adapted 
version of the 14-point MEDAS questionnaire and levels of PA via the International Physical 
Activity Questionnaire (IPAQ). Additionally, participants provide information on age, height, 
weight, medical history, and whether they have regular access to the internet. 
 
Telephone screening 
Participants who satisfy all of the inclusion/exclusion criteria on the online screening 
questionnaire, except for the PA criteria, receive a telephone call (~10 minutes duration) from 
a research team member to probe PA levels, to minimise over-reporting and to improve the 
accuracy of PA estimates.  Probing questions are based on Rzewnicki et al. [42], and involve 
enquiries around exercise duration and intensity (estimated via the effect on breathing). Eligible 






Onsite screening is conducted in a clinical facility at the participant’s local study site (~90 
minutes duration).  Following informed consent (Online Supplementary Material), a series of 
measures are taken to evaluate participant eligibility (Table 2). 
 
Height and weight are measured using standard laboratory techniques for calculation of body 
mass index (BMI), whilst blood pressure (BP) is determined as described in the Outcome 
Measures section. The MoCA is administered, and participants are assessed for subjective 
memory complains via the Cognitive Change Index (CCI) [43]. Further questionnaires are 
administered to ensure the absence of severe depression (Participant Health Questionnaire 
[PHQ-9] score≤10) and anxiety (General Anxiety Disorder questionnaire [GAD-7] score≤10). 
Additionally, a close friend or relative of the participant is asked to complete the Ascertain 
Dementia 8-item informant questionnaire (AD-8; score<2) and the Instrumental Activities of 
Daily Living questionnaire (IADL; score=8) to evaluate memory decline. Finally, participants 
recruited directly from the general public provide a 4 mL blood sample for determination of 
serum total- and HDL-cholesterol concentrations and provide additional medical history 
information for calculation of QRISK2 score.  
 
Randomisation 
Those who pass the onsite screening receive a written invitation to participate in the study. If 
they accept, they are allocated at random to one of the three study arms, with stratification for 





To promote adherence and efficacy, MedEx-UK is a personalised intervention based on an 
individual’s baseline MedDiet profile and/or PA levels, alongside personal food and activity 
preferences. The study aims to increase the MedDiet score by a minimum of 3 points in both 
intervention arms. This target is based on the consistent observation of significant reductions 
in CVD risk and overall mortality associated with a 2-point increase in the score using the 9-
point scale [44,45]; the cognitive benefits associated with a 1.4-1.8 point increase in score in 
the PREDIMED trial [12,14]; and our own analyses in the EPIC-Norfolk cohort showing that 
a 3 point increase in MedDiet score is equivalent to between 1.5 and 5 fewer years of ageing 
on global cognition in older, UK adults [15]. We also aim to increase PA levels (in the 
MedDiet+PA group) to at least 150 minutes of moderate-intensity exercise (or equivalent 
vigorous-intensity exercise minutes) per week and to maintain this level throughout the study, 
in line with World Health Organisation (WHO) recommendations [46].  
 
Delivery of the intervention 
The MedEx-UK study uses three complementary approaches to support behaviour change, 
namely a web-based intervention, group support sessions, and food delivery.  
 
Web-based component 
Participants in the MedDiet and MedDiet+PA groups are given access to an interactive, web-
based, modular platform called LEAP2, which serves as the primary method of delivering the 
behaviour change intervention. LEAP2 is built upon the LEAP platform used in the LiveWell 
Programme (designed to enhance healthy ageing by improving diet, PA and social 
connectedness in older adults [47]) and includes the ‘Eating Well’ module (to increase MedDiet 
adherence) and the ‘Moving More’ module (to increase PA). Participants are encouraged to 
revisit the Eating Well and Moving More modules frequently to monitor their progress. In 
addition, the LEAP2 platform includes a diary feature to help participants plan their meals and 
PA, and serves as a central hub through which participants can ‘link out’ to the dietary 
assessment and food delivery elements of the MedEx-UK trial, alongside information on 
locally available PA opportunities. Members of the public provided feedback on iterations of 
the LEAP2 platform to maximise efficacy and usability.  
 
Eating Well 
The Eating Well module begins with a dietary screening questionnaire (MEDAS), which 
provides an overall MedDiet score (on a 14 point scale). This allows LEAP2 to identify those 
MedDiet goals that are being met, and to give recommendations on those goals that are not. 
The participant is asked to focus on increasing their score by ≥3 points. To facilitate this 
increase, the Eating Well module provides MedDiet-specific recipes, alongside suggestions for 
incorporating MedDiet food items into the participants favourite meals (so-called ‘MedDiet 
Hacks’), advice on consuming takeaway and restaurant foods, and tips on overcoming key 
barriers associated with dietary change [48].   
 
Moving More 
The Moving More module follows a similar structure to the Eating Well module and begins 
with a PA questionnaire (IPAQ) to determine the participant’s current PA levels. LEAP2 
allocates the participant bronze (≥100 minutes of moderate or 50 minutes of vigorous-intensity 
PA per week), silver (≥120 minutes of moderate or 60 minutes of vigorous-intensity PA per 
week) or gold level (≥150 minutes of moderate or 75 minutes of vigorous-intensity PA per 
week) awards for achieving set PA targets. Reflective of our inclusion criteria, participants 
begin the intervention below the bronze level, with aims to increase and maintain PA equivalent 
to the gold level. Participants are asked to set a goal of moderate and/or vigorous activity in 
minutes per week and LEAP2 provides tailored PA suggestions based around participants 
preferences for cost, intensity, and group or individual exercises (list of suggestions 
summarised in the Online Supplementary Material), and guides participants through 
overcoming key barriers associated with increasing PA levels.  
 
Group sessions component 
Participants in the two ‘active’ intervention arms (MedDiet and MedDiet+PA groups) receive 
face-to-face support via four, 2-2.5 hour group session (conducted at weeks 0, 2, 4, and 12) to 
complement the LEAP2 platform. The inclusion of the group sessions is based on evidence that 
‘human support’ in the form of group sessions improves adherence to internet-delivered 
interventions [49]. The content and delivery of the group sessions are informed by evidence 
synthesis and PPI consultation. Group sessions aim to empower participants to engage with the 
process of achieving ambitious behavioural targets and encourage them to access available 
support, including other participants and the LEAP2 platform [50]. Each group consists of 6 
participants and up to 6 ‘supportive others’, who are encouraged to attend to provide social 
support for participants.  
 
Group facilitators recruited from the community were provided with extensive training, 
including an in-person 2-day training course and training materials for at-home learning, in 
social interaction, group facilitation, and behaviour change theory and techniques. Evidence-
based training strategies include instruction, demonstration, practice and feedback. We 
promote fidelity of delivery across sites and facilitators through standardised training, ongoing 
support, and use of group session materials and example ‘script’. However, we are balancing 
fidelity (delivery of group sessions as planned) with the need to adapt the content and delivery 
to context (e.g., geographical area) and participants (age, gender and culture). Such adaptations 
can promote engagement of the participants and gives them a sense of ownership over the 
group sessions and the process of behaviour change.  
 
Food provision 
Increasing MedDiet adherence in a ‘real world’ setting has only modest cost implications (high 
versus low MedDiet adherence was associated with an increased dietary cost of ~ £0.20/d in a 
UK cohort [51]). However, to ensure perceived cost or logistics is not a barrier to increasing 
MedDiet score, participants are provided with £30/ week in vouchers for an online food retailer 
or, in cases where online food delivery is not possible (e.g. due to delivery restrictions to rural 
areas), vouchers for a supplier of their choice. A link to the online food retailer is provided on 
the LEAP2 platform, and participants are asked to use the vouchers to purchase foods 
contributing towards their MedDiet targets. 
 
Control group 
The control group, undergo ‘usual care’ and are thus provided with general guidelines for those 
with a moderately elevated QRISK2 score [52], comprising publically available dietary and 
PA advice viz. leaflets from the British Heath Foundation and links to the NHS ‘Livewell’ and 
‘Eatwell’ websites.  Participants are given a brief presentation on the importance of a control 
group, at an initial group session (week 0). At the end of the trial, the control group will receive 





Outcome measures  
Dietary intake 
At baseline and week 24, participants complete five, non-consecutive 24-hour dietary recalls 
(~10-20 minutes duration per recall) on four weekdays and one weekend day, using the 
validated online dietary reporting software Intake24 [53–55]. At weeks 6 and 12, participants 
also complete 24-hour dietary recalls on three non-consecutive days, including two weekdays 
and one weekend day to monitor interim dietary changes. These dietary data are used to 
calculate a MedDiet score using the 14-point MEDAS scale. Participants also complete an 
online version of the 14-point MEDAS at each of these time points to allow comparison and 
cross-validation of the two assessment methods.  
 
Physical activity  
Participants are asked to wear an activity monitor (Vivosmart 3, Garmin) throughout the 24-
week intervention period. The activity monitors are set to show the time and date; however, 
they are prevented from accessing any activity-based data because use of activity trackers alone 
has been shown to influence behaviour [56]. The participant’s age, height and weight are 
entered when setting up the device to improve accuracy. The activity monitor monitors total 
step count, heart rate and energy expenditure.  
 
Cognitive function 
Global cognitive function, as determined by a composite score based on an extended version 
of the neuropsychological test battery (NTB; Table 3), is measured [59]. This is calculated as 
Z-scores standardised to the baseline mean and SD, with higher scores indicating better 
performance. Sub-domain Z-scores are evaluated for executive function, memory, and 
processing speed. The executive function domain is calculated using scores from the Controlled 
Word Association Test (COWAT), Category Fluency Test (CFT), Trail Making Test (TMT) A 
and B, Hayling Sentence Construction Task, and Digit Span. The memory domain Z-score 
includes results from the Verbal Paired Associates (immediate and delayed), Visual Paired 
Associates (immediate and delayed), and Rey Auditory Verbal Learning Test (RAVLT; 
immediate and delayed), whilst the processing speed domain z-score is calculated from the 
Digit Symbol Substitution Task and Hayling Sentence Completion Task.     
 
Extended NTB score was the primary outcome in the FINGER trial [35] where it was 
responsive to intervention. Its use in MedEx-UK will allow trial comparability, although in our 
study we have used the Hayling Sentence Completion Task as an alternative to the Stroop test 
and we have not included the Concept Shifting Test, as most of the related processes are 
covered via the TMT. We include assessments of spatial navigation via the virtual reality 
Supermarket Trolley Task [57–60] and the Sea Hero Quest Test [61]. Spatial navigation has 
been shown to be an earlier cognitive symptom in preclinical dementia than episodic memory 
[62,63].  The duration of each cognitive assessment is ~ 90 minutes.  
 
Neuroimaging 
Magnetic resonance imaging (MRI) is conducted at baseline and 24-weeks to assess regional 
structural integrity and blood flow (~60 minutes duration per scan). The following sequences 
are used; i) T1-weighted 3D gradient-echo MR sequence to evaluate brain structure, ii) T2-
weighted scan, T2* and T2 FLAIR to allow for vascular characterisation, such as white matter 
hyperintensities, iii) Arterial Spin Labelling to measure regional cerebral blood flow, iv) 
Diffusion Tensor Imaging (DTI) involving a 30-direction diffusion-weighted echo-planar 
imaging scan to assess the integrity of white matter, v) resting-state functional MRI (fMRI) to 
evaluate regional interactions in the brain that occur in a resting or task-negative state when a 
participant is not performing an explicit task. 
 
Biological samples 
Blood, urine and faecal samples are collected at baseline and at 24-weeks to establish APOE 
genotype and selected biomarkers of cardiometabolic and cognitive health (e.g. plasma 
glucose, lipids, antioxidant and inflammatory levels, BDNF and nitric oxide biomarkers, gut 
microbiota speciation, and metabolomic profiles in dry blood spots, urine, and faecal samples). 
A total of 29 mL blood is collected in the fasting state, and whole blood, red blood cells, plasma, 
serum and platelets are aliquoted and stored at -80C◦ until further analysis. Protein saver cards 
(Whatman, GE Healthcare, UK) are used to obtain dry blood spot samples. At-home spot urine 
samples are collected on 4 days/ week (3 x weekdays, 1 x weekend day), whilst faecal samples 
are collected on the day prior to the baseline and end-point visits. Both urine and faecal samples 
are stored at -80C◦ until further analysis  
 
Blood pressure 
Clinic-based blood pressure (BP) of the brachial artery is determined following a 5-minute rest 
period using calibrated, automated sphygmomanometers. BP is measured in triplicate, with one 
minute rest period between measures [64]. In addition, 24-hour ambulatory BP is measured 
using a portable monitor consisting of an inflatable cuff attached to a small monitoring device.  
Readings are taken every 20 minutes from 06:00 to 22:00 and every hour overnight from 22:00 





Endothelial function is measured using flow-mediated dilation (FMD), which assesses the 
response of the endothelia to shear stress [65]. The brachial artery is identified with an 
ultrasound transducer, and changes in the artery diameter in response to hyperaemia are 
recorded using border detection software. The diameter is recorded continuously throughout 
the procedure including for 3 minutes at baseline, followed by 5 minutes of occlusion of the 
forearm (sphygmomanometric cuff inflated to 220 mmHg to induce hyperaemia), then 5 
minutes post-deflation.   
 
Data storage, management, and dissemination 
To maintain anonymity, participants are allocated a numerical identifier. All raw and analysed 
data from tests and questionnaires will be assigned a code and will not contain information that 
could enable identification of individual participants. Data will be stored in locked filing 
cabinets and any electronic information will have restricted access and/or password protection 
as appropriate. All adverse events and participant medication will be documented. Study results 
will be disseminated via conference presentations, peer-reviewed publications, and public 
outreach events.  Participant data will be anonymised in all publications. Data will be retained 
for 15 years following publication.  Access to data will be determined by a trial management 
committee consisting of AMM, JCM, MS and SA.   
 
Statistics 
This study aims to recruit 108 participants. Assuming a 20% drop-out rates, we predict about 
90 will complete the study, 30 participants in each arm. Hence, we will obtain a 95% 
confidence interval for the mean difference between the TAU (treatment as usual) and 
combined treatment arms of + 0.75 points either side of the point estimate. The smallest 
detectable change in MedDiet score with 90% power and 5% size is 1.23 points, well inside 
our minimum target for dietary change of 3 points, suggesting we will have a sufficiently 
precise estimate of whether a dietary change is achievable in this trial.  We will also compare 
individual arms descriptively, to provide an indication of whether the PA intervention effects 
the MDP change achieved, and explore associations between intervention engagement (LEAP2 
and group sessions) and behavioural outcomes. A total of 90 participants to completion will 
have 90% power to detect a difference of 1.4 points between these groups. 
 
DISCUSSION 
The MedEx-UK trial aims to evaluate the feasibility and acceptability of a multi-dimensional 
intervention in an older, UK-based cohort at risk of dementia. This study will provide crucial 
information on behaviour change (MedDiet score and PA levels) and on cognitive, 
neurological, vascular, and physiological responses to the intervention, to inform the power 
and design of a follow-on, full-scale efficacy trial.   
 
Strengths and limitations 
A key strength of the MedEx-UK trial is the personalised nature of the intervention. To date, 
most multi-domain interventions have prescribed a ‘one size fits all’ approaches to behaviour 
change, where recommendations are made to consume specific food products [41] or to 
undertake specific exercises [34]. In contrast, MedEx-UK encourages participants to take an 
active role in selecting lifestyle changes which fit with their individual needs (identified 
through the diet and activity screening questionnaires) and personal food and activity 
preferences, which may help aid motivation and improve the efficacy of the intervention [66–
69]. From a dietary perspective, results from our analysis of the EPIC-Norfolk cohort [15] 
indicate that the beneficial effects on cognition are related to consumption of the MedDiet as a 
whole, rather than being driven by an individual food group. This suggests that individuals 
have a degree of dietary flexibility and are encouraged to focus on MedDiet components that 
meet their personal food preferences. The design of the PA intervention used in the study 
accommodates key practices identified in promoting PA in older adults, including the 
multidimensional approach, principles of behaviour change and gradual increases in intensity 
[70]. Furthermore, reducing barriers against inactivity identified in older adults [71], by 
allowing the participants to self-select activities, will promote adherence to PA. Such 
personalisation and flexibility may improve adoption of this dietary pattern and facilitate 
increased PA.  
 
MedEx-UK targets individuals deemed to be ‘at-risk’ of dementia, based on their 
cardiovascular risk profile (QRISK2 score ≥ 10), given the strong links between poor 
cardiovascular health and increased risk of cognitive decline and dementia [37–40]. Such 
targeting will allow us to capture the most vulnerable population who are most likely to benefit 
from lifestyle modifications. Indeed, in our analysis of data from the EPIC-Norfolk cohort, we 
showed that associations between MedDiet adherence and reduced risk of poor cognitive 
performance were apparent only in individuals with a high CVD risk profile [15]. Furthermore, 
a recent systematic review found that exercise affected cognitive performance positively in 
those with known vascular disease [72].   
 
Consistent with most other RCTs in this area [73], it is not possible to blind participants to the 
intervention. This increases the risk of expectation bias which could result in more favourable 
outcomes compared with the control group [74]. Additionally, this trial does not include a PA 
only arm, so the effects of PA alone (rather than the potentially additive effects of diet and PA) 
cannot be elucidated.  
Conclusions 
The MedEx-UK trial will provide insight into the feasibility and acceptability of a multi-
dimensional lifestyle intervention to promote healthy brain ageing in a UK cohort. If 
successful, this feasibility trial will inform a longer and larger trial designed to test the efficacy 
of the lifestyle-based intervention in reducing dementia risk with the long-term aim of 
diminishing the mounting social and financial burden caused by this debilitating 
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TABLES 
Table 1: Inclusion and exclusion criteria for the MedEx-UK trial 
Inclusion Criteria 
• Male and female aged 55-74 years 
• QRISK2 score ≥ 10% 
• Stable use of any prescribed medication for at least four weeks 
• Understands and is willing and able to comply with all study procedures 
• Has access to, and able to use, the internet and a computer/tablet 
• Normal, or corrected to normal, vision and hearing 




• Diagnosis of Alzheimer’s disease, other forms of dementia, Mild Cognitive 
Impairment, or other significant neurological disorder 
• Cognition not within the normal range, based on a score of less than 23 on the 
Montreal Cognitive Assessment (MoCA); or indication of cognitive decline, based 
on a score of 2 or more on Ascertain Dementia (AD-8) 
• Evidence of impairment of Instrumental Activities of Daily Living (IADLS) 
• Moderate to severe depression, assessed by the Patient Health Questionnaire (PHQ-
9) 
• Moderate to severe anxiety, assessed by the Generalised Anxiety Disorder A 
(GAD-7) questionnaire 
• Current psychotic illness (delusional disorder/schizophrenia) 
• History of serious mental illness know to affect cognition (schizophrenia, 
schizoaffective disorder, bipolar disorder) 
• Subjects with other clinically diagnosed psychiatric disorders likely to affect the 
cognitive measures (as judged by a clinical advisor) 
• HIV positive 
• Past history or previous MRI evidence of brain damage, significant head trauma 
(including loss of consciousness as a result), brain surgery, stroke, or serious 
neurological disorders 
• History of alcohol or drug dependency in the last two years 
• Subjects with existing diagnosed gastrointestinal disorders likely to impact study 
results (as judged by a clinical advisor) 
• History of any major cardiovascular event, such as a myocardial infarction, stroke 
or TIA 
• Severe chronic obstructive pulmonary disease 
• Cancer, or cancer treatment within the last 12 months 
• Diagnosis of type 1 or type 2 diabetes diagnosed less than three months ago 
• Clinical diagnosis of liver or kidney disease (level 3 and above) 
• Diagnosed Epilepsy 
• Subjects with any other existing medical conditions likely to influence the study 
measures (as judged by a clinical advisor) 




• Habitual Mediterranean Diet Score (MDS) of more than 8 (on the 14-point MEDAS 
questionnaire) 
• Habitual physical activity of more than 90 minutes moderate activity per week, 
assessed using the International Physical Activity Questionnaire short form 
• Currently engaged in a weight loss, other dietary, or physical activity intervention 
 
Other 
• Currently, a participant or have participated in any other study involving an 
investigational product in the last four weeks 




Table 2: A summary of measures obtained during the onsite screening visit 
Variable Methods 
Height (cm) and weight (kg) Stadiometry and calibrated, electronic scales 
Resting blood pressure 
(mmHg)  
Calibrated, automated sphygmomanometers  
Blood cholesterol 4 ml blood sample  
Cognitive function Montreal Cognitive Assessment (MoCA)  
Subjective memory 
complaints 
Cognitive Change Index (CCI) 
Depression Participant Health Questionnaire (PHQ-9)  
Anxiety General Anxiety Disorder questionnaire (GAD-7)  
Memory decline Ascertain Dementia 8-item informant questionnaire (AD-8) 
and Instrumental Activities of Daily Living questionnaire 
(IADL).  
   
Table 3: Cognitive tests used in the MedEx-UK trial 
Task Time Extended NTB sub-domain 
Part 1 
Total 45-50 
(including instruction time) 
Verbal Paired Associates 9-12 Memory 
Visual Paired Associates 6 Memory 
COWAT 3 Executive function 
CFT 1 Executive function 
Digit Symbol Substitution 2 Processing speed 
TMT A & B 5 Executive function 
Verbal Paired Associates, 
delayed recall* 
5-8 Memory 
Visual Paired Associates, 
delayed recall 
6 Memory 
   
BREAK 
   
Part 2 
Total 45-50 
(including instruction time) 
RAVLT 10-15 Memory 
Hayling Sentence Completion 5-10 Executive function, Response 
inhibition  
Digit Span  3-5 Executive function 
Supermarket Trolley Task 10 Spatial navigation 
RAVLT - delayed recall 3 Memory 














Figure 1: Flow of participants through the MedEx-UK trial.  
 
